<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35983089</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Possible internal viral shedding and interferon production after clinical recovery from COVID-19: Case report.</ArticleTitle><Pagination><StartPage>959196</StartPage><MedlinePgn>959196</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">959196</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.959196</ELocationID><Abstract><AbstractText>A 70-year-old man underwent off-pump coronary artery bypass grafting 28 days after his recovery from coronavirus disease 2019 (COVID-19), which was confirmed by a negative polymerase chain reaction (PCR) test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a nasopharyngeal swab. The PCR test result was also negative for nasopharyngeal sampling 5 days prior to the surgery. However, his redundant saphenous vein and sputum through the endotracheal tube that was taken on the operative day showed the presence of SARS-CoV-2 by PCR. Immunohistochemical analysis of Spike and Nucleoprotein of the saphenous vein showed small clusters of each antigen-positive speckle. Ultrastructural imaging of the saphenous vein showed virus-like particles. The cell-based assay suggested that the patient's serum contained a higher concentration of type-I interferons than that of healthy control sera. These observations suggest that internal viral shedding and, to some extent, innate immune responses continue after COVID-19 recovery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Ito, Okada, Minato and Hattori.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Asuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, School of Medicine, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, School of Medicine, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minato</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, School of Medicine, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Fumiyuki</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Innovative Regenerative Medicine, Graduate School of Medicine, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">type-I interferons</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35983089</ArticleId><ArticleId IdType="pmc">PMC9379344</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.959196</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M&#xf8;ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. (2020) 181:1036&#x2013;45.e9. 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. (2021) 12:698169. 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayed A, Kamel M. Coronaviruses in humans and animals: the role of bats in viral evolution. Environ Sci Pollut Res Int. (2021) 28:19589&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924989</ArticleId><ArticleId IdType="pubmed">33655480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartard C, Chaqroun A, Settembre N, Gauchotte G, Lefevre B, Marchand E, et al. Multiorgan and vascular tropism of SARS-CoV-2. Viruses. (2022) 14:515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8955556</ArticleId><ArticleId IdType="pubmed">35336922</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo JS, Sasaki M, Cho SX, Kasuga Y, Zhu B, Ouda R, et al. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat Commun. (2021) 12:6602. 10.1038/s41467-021-26910-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26910-8</ArticleId><ArticleId IdType="pmc">PMC8594428</ArticleId><ArticleId IdType="pubmed">34782627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. (2020) 20:585&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824445</ArticleId><ArticleId IdType="pubmed">32788708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, et al. Long-term benefits of interferon-&#x3b1; therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat. (2021) 28:1554&#x2013;62. 10.1111/jvh.13598</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13598</ArticleId><ArticleId IdType="pubmed">34448324</ArticleId></ArticleIdList></Reference><Reference><Citation>Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis. (2016) 20:645&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">27742005</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. (2014) 32:513&#x2013;45. 10.1146/annurev-immunol-032713-120231</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120231</ArticleId><ArticleId IdType="pmc">PMC4313732</ArticleId><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas AL, Ahrens P, Bright PM, Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem. (1987) 262:11315&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440890</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber MA, Okasha H, Khorshed F, Samir S. A novel cell-based in vitro assay for antiviral activity of interferons &#x3b1;, &#x3b2;, and &#x3b3; by qPCR of MxA gene expression. Recent Pat Biotechnol. (2021) 15:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">33183215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. (2020) 323:2249&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32374370</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Mao T, Li S, Wu L, Xu X, Li H, et al. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. medRxiv [Preprint]. (2020): 10.1101/2020.04.22.20071258</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20071258</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F, Wan P, Wei Q, Wei G, Yu Y. Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: a case report and literature overview. J Med Virol. (2022) 94:3133&#x2013;7. 10.1002/jmv.27694</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27694</ArticleId><ArticleId IdType="pmc">PMC9088484</ArticleId><ArticleId IdType="pubmed">35274321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>